For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Surgery Partners Inc’s stock clocked out at $22.82, up 0.57% from its previous closing price of $22.69. In other words, the price has increased by $0.57 from its previous closing price. On the day, 1.05 million shares were traded. SGRY stock price reached its highest trading level at $22.92 during the session, while it also had its lowest trading level at $22.62.
Ratios:
To gain a deeper understanding of SGRY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.69. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.
On October 14, 2024, UBS started tracking the stock assigning a Buy rating and target price of $38.UBS initiated its Buy rating on October 14, 2024, with a $38 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 27 ’25 when Wayne DeVeydt bought 11,865 shares for $22.90 per share.
Wayne DeVeydt bought 25,000 shares of SGRY for $572,500 on Aug 26 ’25. On Aug 21 ’25, another insider, Wayne DeVeydt, who serves as the Director of the company, bought 100,000 shares for $22.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2925729280 and an Enterprise Value of 8361249280. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.90 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 2.583 whereas that against EBITDA is 12.965.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.76, which has changed by -0.2739421 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.90, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is 2.79%, while the 200-Day Moving Average is calculated to be -0.12%.
Shares Statistics:
It appears that SGRY traded 1.72M shares on average per day over the past three months and 1287510 shares per day over the past ten days. A total of 128.21M shares are outstanding, with a floating share count of 75.97M. Insiders hold about 40.74% of the company’s shares, while institutions hold 74.36% stake in the company. Shares short for SGRY as of 1755216000 were 12747748 with a Short Ratio of 7.42, compared to 1752537600 on 11846554. Therefore, it implies a Short% of Shares Outstanding of 12747748 and a Short% of Float of 21.079999.
Earnings Estimates
The current assessment of Surgery Partners Inc (SGRY) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.47, with high estimates of $0.61 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.01, with 12.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $824.04M. It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 12 analysts are estimating revenue of $930.64M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.
A total of 12 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 12 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.
